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Sepsis is a major cause of mortality in intensive care units. 
Sepsis is a leading cause of death in both developed and 
underdeveloped countries and the incidence is increasing 
each year; worldwide, sepsis aﬀ ects about 18 million 
people every year [1]. Sepsis has a mortality rate of around 
25% for uncomplicated sepsis, rising to 80% in those 
patients who go on to develop multiple organ failure, so 
the number of deaths is considerable. Th e precise 
pathogenesis of sepsis-induced organ failure is unknown, 
but changes that result in altered oxidative phosphory-
lation and ATP production occur in mitochondria.
Mitochondrial production of reactive oxygen 
species
Mitochondria are both the major source of intracellular 
reactive oxygen species (ROS) in a resting cell and a 
major target [2,3]. Mitochondria produce more than 90% 
of the body’s cellular energy in the form of ATP via 
oxidative phosphorylation. ROS can be generated from 
complexes I and III of the mitochondrial electron 
transport chain (ETC), by the tricarboxylic acid (TCA) 
cycle enzymes aconitase and α-ketoglutarate dehydro-
genase, by non-TCA cycle enzymes (including pyruvate 
dehydrogenase and glycerol-3-phosphate dehydrogenase), 
and by monoamine oxidases and cytochrome b5 
reductase, located in the outer mitochondrial membrane. 
Th e inner membrane of the mitochondria has low 
permeability in order to permit energy conservation in 
the form of an electron and pH gradient over the mem-
brane. However, mitochondria can undergo a general ized 
increase of permeability of the inner membrane, called 
permeability transition. Th e permeabi li zation of the 
membrane is due to the opening of the permeability 
transition pore, which is an early key event in apoptosis, 
causing activation of the caspase cascade through release 
of cytochrome c. Th e pore transition is sensitive to 
oxidative stress. An overview of mitochondrial ROS 
produc tion is presented in Figure 1.
In addition to producing ROS, the mitochondrial 
respiratory chain is capable of producing nitric oxide and 
other reactive nitrogen species (RNS), including (notably) 
peroxynitrite formed from the reaction of nitric oxide 
with superoxide anion. RNS can oxidize proteins and 
nucleic acids an d cause nitrozati on or nitration of cellular 
targets, including proteins and glutathione. Th ree iso-
zymes of nitric oxide synthase (NOS) catalyze the 
production of nitric oxide from L-arginine in the 
presence of NAD(P)H and oxygen, although the oxygen 
concentration threshold below which this pathway does 
function is unclear. Th e existence of a mitochondrial 
form of NOS was proposed [4,5] but this remains 
controversial [6]. It has also been suggested tha t the 
respiratory chain can reduce nitrite to nitric oxide and 
that this pathway is oxygen-independent and is activated 
by hypoxia [7]. However, this review will concentrate on 
mitochondrial ROS and antioxidant protection.
Mitochondria have other important roles in both physio-
logical and pathophysiological processes, including calcium 
homeostasis, cell signaling pathways, trans criptional 
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regulation, and apoptosis [7-9]. Th us, mitochondrial ROS 
are important for normal cellular function and survival, 
and a complex but tightly con trolled scavenging system 
allows these functions while limiting damage. In normal 
healthy cells, oxidation and the generation of ROS occur 
at a controlled rate, but under high stress conditions or in 
disease states (including sepsis), ROS production is 
increased, causing changes to proteins and lipids.
Figure 1. Overview of mitochondrial reactive oxygen species (ROS) production. ROS production by mitochondria can lead to oxidative 
damage to mitochondrial proteins, membranes, and DNA, impairing the ability of mitochondria to synthesize ATP and other essential functions. 
Mitochondrial oxidative damage can also increase the tendency of mitochondria to release cytochrome c (cyt c) into the cytosol by mitochondrial 
outer membrane permeabilization (MOMP), leading to apoptosis. Mitochondrial ROS production leads to induction of the mitochondrial 
permeability transition pore (PTP), which makes the inner membrane permeable to small molecules. Mitochondrial oxidative damage contributes 
to a wide range of pathologies, and mitochondrial ROS act as a reversible redox signal modulating the activity of a range of cellular functions. 
Reproduced from [2] with permission.
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Antioxidant protection
Under normal conditions, mitochondria are protected 
from damage by ROS via several interacting antioxidant 
systems, but when antioxidant protection is over-
whelmed, oxidative stress initiates damage to nucleic 
acids, proteins, and lipids in mitochondria, resulting in 
loss of enzyme function in the ETC and eventually 
leading to mitochondrial dysfunction and impairment of 
ATP production [3,10]. Endogenous antioxidant systems 
can also be damaged via protein oxidation, and per-
oxidation of cardiolipin leads to the dissociation of 
cytochrome c (compromising the function of cytochrome c 
oxidase), reduced ATP production, and further increased 
generation of ROS [3,9,10]. A complex network of well-
deﬁ ned and tightly regulated antioxidant defense systems 
is present in mitochondria and acts at several levels. 
Th ese systems use both enzymatic and non-enzyme path-
ways to scavenge mitochondrial ROS and include 
manganese-containing superoxide dismutase (MnSOD), 
the glutathione and thioredoxin systems, peroxyredoxins, 
sulﬁ redoxins, cytochrome c, peroxidase, and catalase 
[11,12]. An increase in ROS production can also occur as 
a consequence of depletion or a defect in the mitochon-
drial antioxidant system. Increased ROS production 
under such conditions has been ascribed to a self-
regenerating ROS production facilitated by ROS-induced 
ROS release. Th is increase in oxidative stress results in 
further damage of mitochondrial proteins that are highly 
sensitive to oxidative stress. A point is reached at which 
the scavenging systems are completely overwhelmed, 
leading to a state of so-called ‘toxic oxidative stress’ [13].
Oxidative stress in sepsis
Oxidative stress occurs when the balance between 
production of ROS and antioxidant protection is disrup-
ted, leading to the activation of pathways that aﬀ ect cell 
diﬀ erentiation and apoptosis. Oxidative stress has been 
reported over the last decade in patients with sepsis [14], 
as shown by increased levels of lipid peroxides and direct 
detection of circulating radicals [15-17], decreased anti oxi-
dant capacity associated with non-survival [18,19], decreased 
concentrations of individual antioxidants [15,20,21], 
detectable circulating redox-reactive iron [22], ischemia-
reperfusion leading to xanthine oxidase activation [16], 
and abnormal handling of exogenous antioxidants [23]. 
Oxidative stress initiates inﬂ ammatory responses and cell 
activation, and elevated activation of the redox-sensitive 
transcription factor nuclear factor-kappa-B (NF-κB) in 
patients with sepsis has been described [24-26].
Mitochondrial dysfunction and organ damage 
in sepsis
It is not certain whether mitochondrial dysfunction is the 
primary event that leads to oxidative stress and further 
mitochondrial damage or, conversely, whether oxidative 
stress contributes to mitochondrial dysfunction. What is 
known is that a self-sustaining and self-amplifying feed-
forward cycle between ROS generation and mitochon-
drial impairment occurs. Oxidative stress has been 
reported consistently in patients with sepsis, and 
mitochondrial dysfunction as a result of oxidative stress 
has been suggested as a causative factor in the develop-
ment of organ failure in sepsis [27,28]. Mitochondrial 
dysfunction has been described in rat models of sepsis 
[29], and a study in baboons treated with live Escherichia 
coli found decreased complex I/II activities in heart 
mitochondria [30]. In cats, deranged mitochondrial 
ultra structure and impaired respiratory activity were 
observed 4 hours after lipopolysaccharide (LPS) (endo-
toxin) admin is tration [31], and in livers from patients 
who had died of severe sepsis, hypertrophic mitochondria 
with reduced complex I and IV activity were observed 
[32]. Deranged mitochondrial redox state [33] and an 
asso cia tion between antioxidant depletion and mito-
chon drial dysfunction related to organ failure and 
eventual outcome have been reported in patients with 
sepsis [34].
Since oxidative damage to mitochondria is central to 
the pathology of sepsis, antioxidants could be potential 
thera pies. However, no studies have yet provided 
conclusive evidence of the beneﬁ cial eﬀ ect of antioxidant 
supplemen tation in critically ill patients [14,35]. Th is may 
be because the antioxidants are distributing throughout 
the body and are not accumulating in the mitochondria, 
where they are most needed. Antioxidants targeted 
speciﬁ  cally at mito chon dria have therefore been 
proposed.
Th e desired eﬀ ect of a drug or gene targeted at 
mitochondria in organs can be achieved only if the 
bioactive molecule is taken up by the required organ or 
cell type or both and accumulates in the desired sub-
cellular location (in this case, mitochondria). Th e 
speciﬁ city of distribution and penetration in organs and 
consistent delivery and activity in mitochondria are 
paramount. Antioxidants have been targeted selectively 
to mito chon dria by several means and have been shown 
to be eﬀ ective at reducing mitochondrial damage and 
apoptosis in vitro and in animal models of several 
diseases involving oxidative stress.
Targeting antioxidants to mitochondria
Strategies to reduce the mitochondrial damage caused by 
sustained oxidative stress as a therapeutic approach 
include augmenting ROS scavenging by antioxidants that 
(a) are delivered speciﬁ cally to mitochondria, (b) act 
where needed in the mitochondria, or (c) pharmaco-
logically or genetically increase endogenous expression 
of mitochondrial antioxidant systems.
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Lipophilic cations
One approach is to target antioxidants selectively to 
mitochondria by conjugating an antioxidant to lipophilic 
cations that accumulate within mitochondria, driven by 
the mitochondrial membrane potential. For example, 
MitoQ consists of the lipophilic triphenylphosphonium 
(TPP) cation attached to the ubiquinone antioxidant 
moiety of the endogenous antioxidant co-enzyme Q10 
[36]. Th e lipophilic TPP cation enables MitoQ to be taken 
up rapidly through the plasma and mitochondrial 
membranes without the requirement for a carrier, and 
the large membrane potential (negative inside) across the 
mitochondrial inner membrane causes MitoQ to 
accumulate several hundred-fold within mitochondria 
[36-38]. Within mitochondria, the MitoQ adsorbs to the 
matrix surface of the inner membrane and is recycled to 
the active ubiquinol antioxidant by the respiratory chain 
(Figure 2).
Antioxidants that accumulate within the matrix 
provide better protection from oxidative injury than un-
targeted antioxidants. MitoQ has been shown to protect 
cells from apoptosis and inhibits hydrogen peroxide-
induced growth factor receptor signaling [36-40]. It also 
prevented cell death induced by hydrophobic bile acids, 
via eﬀ ects on nitric oxide synthesis, in an in vitro study of 
hepatocytes [41]. It has been tested in a number of animal 
models of disease: feeding MitoQ to rats decreased heart 
dysfunction, cell death, and mitochondrial damage upon 
subsequent ischemia-reperfusion in isolated hearts [42], 
protected endothelial cell function and damage to 
mitochondrial enzymes in a rat model of oxidative stress 
[43], and prevented mitochondrial dysfunction in a rat 
model of nitroglycerin tolerance [44]. In addition, MitoQ 
has been developed as a pharmaceutical for oral use in 
humans [45], and in phase II trials, it has shown 
protection against liver damage in patients with hepatitis 
C virus [46].
MitoVitE is a TPP-conjugated form of tocopherol 
(vitamin E). Like MitoQ, MitoVitE protects mitochondria 
and whole cells from oxidative stress induced by several 
processes, inhibiting lipid peroxidation; blocking apop-
tosis; inhibiting cytochrome c release, caspase-3 activa-
tion, DNA fragmentation, inactivation of complex I and 
aconitase, and overexpression of transferrin receptor; and 
restoring mitochondrial membrane potential and proteo-
somal activity [36,38,40]. MitoVitE has been shown to be 
many times more eﬀ ective than the non-targeted water-
soluble vitamin E analog, Trolox (F. Hoﬀ mann-La Roche 
Ltd., Basel, Switzerland).
Other compounds have been conjugated to TPP. For 
example, ebselen, a selenium-containing compound with 
peroxidase activity, has been conjugated to TPP to form 
MitoPeroxidase. MitoPeroxidase was only slightly more 
eﬀ ective than ebselen in preventing oxidative damage to 
mitochondria in contrast to the other TPP-based 
antioxidants MitoQ and MitoVitE [47]. Th is is because 
most of the MitoPeroxidase is conjugated to thiols and 
this prevents its accumulation in mitochondria to the 
same degree as MitoQ and MitoVitE. Other investigators 
have favored conjugating plastoquinone, a plant quinone 
needed for photosynthesis, to TPP to form a molecule 
named SkQ. Th is has been shown to protect cells against 
oxidative stress in vitro and against ischemia-reperfusion-
mediated cardiac dysfunction in rats (reviewed in [48]).
Hemigramicidin-TEMPOL conjugates
Another strategy used the stable nitroxide radical 
TEMPOL (4-hydroxy-2,2,6,6,-tetramethyl piperidine-1-
oxyl), which accepts an electron to form the radical 
scavenger hydroxylamine. TEMPOL is also able to 
dismute superoxide anion catalytically and has a catalase-
like action that limits hydroxyl radical formation from 
hydrogen peroxide. By conjugating TEMPOL to frag-
ments of the antibiotic, gramicidin-S, which has a high 
aﬃ  nity for mitochondrial membranes, the com pound 
can be targeted to mitochondria [49]. Such conju gates 
were shown to localize into mitochondria, inhibit super-
oxide release, and prevent apoptosis in cells. In an animal 
Figure 2. If an antioxidant is attached to triphenylphosphonium, 
it accumulates several hundred-fold within mitochondria in 
cells and selectively blocks mitochondrial oxidative damage 
and mitochondrial redox signaling. Targeted antioxidants include 
derivatives of the endogenous antioxidants ubiquinol (MitoQ) and 
α-tocopherol (MitoVitE).
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model of hemorrhagic shock, hemigramicidin-TEMPOL 
was more eﬀ ective than non-targeted TEMPOL in 
prevent ing gut hyperpermeability in exteriorized ileum, 
decreasing cardiolipin peroxidation and caspase activa-
tion [50]. Administration of hemigramicidin-TEMPOL to 
rats during hemorrhage decreased mortality rate 
compared with control animals [51].
Antioxidant peptides
Use has also been made of antioxidant peptides contain-
ing speciﬁ c amino acid sequences that allow penetration 
into cells and concentration in mitochondria. Th ese 
molecules were designed by HH Szeto and PW Schiller 
and so were named SS peptides. Th ey are small synthetic 
peptides (fewer than 10 amino acids) with basic amino 
acid residues providing positive charges at physiological 
pH. Th ey are stable in aqueous solution, resist peptidase 
degradation, and freely penetrate by passive diﬀ usion 
into a variety of cell types, and mitochondrial uptake is 
estimated to be 1,000- to 5,000-fold compared with extra-
mitochondrial concentration [52].
Th e mechanism behind the selective targeting of the 
peptides to the mitochondrial inner membrane is not 
understood. Th e inner mitochondrial membrane is 
unique in its high density of cardiolipin, and the selective 
partitioning may be a result of electrostatic interaction 
between these cationic peptides and anionic cardiolipin. 
Some of the SS peptides have antioxidant properties and 
can dose-dependently scavenge hydrogen peroxide, 
hydroxyl radical, and peroxynitrite and limit lipid 
peroxidation (Figure  3). Th e potentially independent 
mitochondrial uptake of these peptides may be an 
advantage when dealing with diseased mitochondria with 
reduced mitochondrial poten tial. Th ere have been no 
studies of these agents in models of sepsis.
Increasing endogenous mitochondrial antioxidants
Redox homeostasis in mitochondria is regulated by 
various antioxidant mechanisms, including glutathione, 
thioredoxin, and peroxiredoxins. Glutathione is the most 
abundant non-protein thiol in cells and plays an impor-
tant role in antioxidant defense mechanisms. Mitochon-
dria cannot synthesize glutathione so it is synthesized in 
the cytoplasm and transported into the mitochondria by 
dicarboxylate and 2-oxoglutarate carriers. Choline esters 
of glutathione N-acetyl-l-cysteine are hydrophilic anti-
oxidants that concentrate in mitochondria and increase 
available glutathione. Th ese compounds reduce oxidative 
stress-induced mitochondrial depolarization in isolated 
mitochondria and intact myocytes and neurones in vitro 
[53], but there are no studies in models of sepsis.
Other techniques to increase endogenous antioxidant 
protection include genetic approaches, such as adenoviral 
transfection with MnSOD. In both alcohol and 
ischemia-reperfusion-induced oxidative stress in rats, 
adenoviral transfection of the human MnSOD gene 
resulted in upregulation of MnSOD activity in liver, with 
reduced hepatic oxidative damage [54,55].
Superoxide dismutase mimetics
Non-protein mitochondrial superoxide dismutase 
mimetics have been developed to allow uptake into the 
mitochondrion to scavenge ROS. Th e mitochondrial 
MnSOD mimetics MnTBAP and Mn(III) meso-tetrakis 
(N-methylpryidinium-2-yl) porphyrin (MnTE-2-Py5+) 
accumulate in heart mitochondria following intra peri-
toneal injection in animals and reduced mitochondrial 
ROS production in an ischemia-reperfusion model [56].
Other approaches
Melatonin (N-acteyl-5-methoxytryptamine) is synthe sized 
in several organs, with higher levels in mitochon dria, and 
is both lipophilic and hydrophilic. It has been identiﬁ ed as 
having anti-inﬂ ammatory and antioxidant activity, 
scavenging hydrogen peroxide and augmenting endoge-
nous antioxidant pathways and downregulating mitochon-
drial nitric oxide production. Melatonin has been shown 
to prevent mitochondrial dysfunction, energy failure, and 
apoptosis and decreased inﬂ ammatory cyto kine release in 
oxidative stress-exposed mito chon dria [57].
α-Lipoic acid is a disulphide derivative of octanoic acid 
with antioxidant activity. It is taken up and reduced 
within mitochondria to dihydrolipoate, an antioxidant 
more powerful than lipoic acid. Lipoic acid inhibits 
nuclear translocation of NF-κB, and numerous studies 
have shown beneﬁ cial eﬀ ects in oxidative stress-induced 
pathological processes [58]. Recently, Ripcke and 
colleagues [59] developed a lipoic acid derivative contain-
ing a cleavable TPP tag that is endogenously cleaved by 
mitochondrial aldehyde dehydrogenase (ALDH-2) after 
mitochondrial accumulation, thus liberating active 
compound (in this case, lipoic acid) and reducing 
oxidative stress in vitro.
Another study exploited the β-oxidation pathway 
within mitochondria to deliver and biotransform pro-
drugs to their corresponding phenolic or thiol anti-
oxidants [60]. Biotransformation to methimazole and 
several phenolic antioxidants was shown to protect 
isolated cardiomyocytes against hypoxia-reoxygenation 
injury, leading the authors to conclude that mitochondrial 
β-oxidation may be a useful delivery system for targeting 
antioxidants to mitochondria. However, the rates of 
biotransformation varied depending on the number and 
position of methyl groups on the pro-drug. In addition, 
loss of membrane potential resulted in loss of bio-
transformation, and this may suggest that this targeting 
approach may be less useful in the presence of 
pathological mitochondrial dysfunction.
Galley Critical Care 2010, 14:230 
http://ccforum.com/content/14/4/230
Page 5 of 9
Targeting antioxidants to mitochondria 
in sepsis
Th ere is a large body of evidence showing that oxidative 
stress-induced mitochondrial dysfunction plays a role in 
sepsis-mediated organ damage such that antioxidants are 
likely to be of therapeutic potential in preventing multiple 
organ failure [27-34]. However, studies of antioxidant 
administration in critically ill patients with sepsis have 
not been convincing [14,35]. Mitochondrial dysfunction 
and downregulation of genes expressing mitochondrial 
proteins occur during sepsis, and recovery after sepsis 
requires the restoration of metabolic processes via 
production of new functional mitochondria to restore 
the energy supply. It has been proposed that the 
protection of mitochondria against oxidative damage 
may be particularly important in patients with sepsis and 
this raises the possibility that mitochondria-targeted 
antioxidants may be of therapeutic beneﬁ t in sepsis-
induced organ failure.
Fink and colleagues [50] suggested that TPP-conjugated 
antioxidants would have limited utility in patients with 
sepsis since the mitochondrial depolarization sometimes 
seen during sepsis may result in poor uptake of TPP-
conjugated antioxidants into mitochondria and increas-
ing the dose may cause membrane depolarization 
through accumulation of the cation. Despite this, MitoQ 
is the most studied of the mitochondria-targeted anti-
oxidants. MitoQ has been shown to have antioxidant and 
anti-inﬂ ammatory eﬀ ects under conditions of sepsis; in 
an in vitro study in which human endothelial cells were 
Figure 3. In vitro assays showing antioxidant properties of SS* peptides. (a) SS-02 dose-dependently scavenges hydrogen peroxide 
as measured by luminol chemiluminescence. (b) SS-02 dose-dependently inhibits linoleic acid peroxidation. Linoleic acid peroxidation was 
induced by 2,2΄-azobis(2-amidinopropane) and detected by the formation of conjugated dienes measured by absorbance at 234 nm. (c) SS-02 
dose-dependently inhibits low-density lipoprotein (LDL) oxidation. Human LDL was oxidized by 10 μM copper sulphate, and the formation of 
conjugated dienes was monitored at 234 nm. (d) Comparison of diff erent SS peptides (100 μM) in slowing the rate of linoleic acid oxidation. 
(e) Comparison of diff erent SS peptides (100 μM) in slowing the rate of LDL oxidation. B, basal rate. Reproduced from [52] with permission. *So 
named after HH Szeto and PW Schiller.
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treated with MitoQ under conditions of simulated sepsis, 
the rate of ROS formation was decreased and mito chon-
drial membrane potential was maintained [61]. In 
addition, both MitoQ and MitoVitE have been shown to 
result in decreased LPS-induced cytokine release in vitro 
[61,62]. In animals, oral, intraperitoneal, or intravenous 
adminis tration of MitoQ or MitoVitE results in rapid 
accumulation in mitochondria of key organs in rats and 
mice; furthermore, biochemical evidence of liver and 
renal dysfunction was decreased in a rat model of acute 
sepsis-induced organ dysfunction when rats were given 
an intravenous infusion of MitoQ immediately after 
initiation of sepsis [61] (Figure 4). In another recent 
study, MitoQ administration at the same time as 
endotoxin also prevented sepsis-induced cardiac dys-
function in septic rats and mice [63].
Other targeted antioxidants have been tried in models 
of sepsis. Hemigramicidin-TEMPOL was shown to have 
anti-inﬂ ammatory eﬀ ects in endotoxin-exposed murine 
macrophages in vitro, and in endotoxin-exposed mice, 
pre-treatment with hemigramicidin-TEMPOL decreased 
NOS expression [50]. Although neither melatonin nor 
lipoic acid is targeted at mitochondria, both of these 
compounds are protective against sepsis-mediated mito-
chon drial dysfunction in animals. Acuña-Castroviejo and 
colleagues [64,65] have undertaken studies using several 
doses of melatonin treatment beginning before cecal 
ligation and puncture in mice, showing attenuated mito-
chondrial dysfunction. Likewise, in an LPS model of 
sepsis in rats pre-treated with lipoic acid, oxidative stress 
was decreased and mitochondrial dysfunction was 
abrogated [66].
Some aspects of these studies are worth pointing out. In 
the studies using hemigramicidin-TEMPOL, mela tonin, or 
lipoic acid, treatments were given before the initiation of 
sepsis [50,64-66]. Although prevention may be better 
than cure, pre-treatment is unlikely to be clinically 
relevant and studies in which treatment is delayed until 
after the onset of sepsis are more likely to represent what 
is practical in patients. Th e ability to use animal studies 
to predict which patients and which dosing regimens are 
likely to be of most beneﬁ t is a challenge. Th ere are both 
limitations and advantages to animal models [67] and 
these should continue to be reﬁ ned in attempts to more 
accurately reproduce human sepsis to maximize clinical 
relevance [68,69]. Despite the fact that all modeling 
approaches face limitations concerning transferability 
and predictability, there is scientiﬁ c validity in animal 
experiments [67], but scientists and clinicians need to 
critically evaluate all stages.
Sepsis has a mortality rate of around 25% for un-
complicated sepsis, rising to 80% in those patients who 
go on to develop multiple organ failure, so the number of 
deaths is considerable. Treatment is currently restricted 
to mainly supportive and reactive treatments, and any 
novel therapy that reduces the incidence and impact of 
organ failure would have immense beneﬁ t. Th e notion 
that mitochondria-targeted antioxidants may be of 
beneﬁ t in sepsis is appealing. Th ere is promise in the 
early data but there is still a long way to go. At present, 
the choice of targeting strategies is still open to debate, 
but increasing the antioxidant defenses of mitochondria 
under conditions of sepsis has been shown to be, in 
theory, a viable strategy. Th erefore, the scene is set for 
Figure 4. Plasma creatinine concentrations (a) and plasma alanine amino transferase (ALT) activity (b) in untreated rats and rats treated 
with lipopolysaccharide (LPS) plus peptidoglycan G (PepG) with triphenylphosphonium control or MitoQ. Results from individual rats are 
shown. P values are Mann-Whitney U tests with Bonferroni correction. Reproduced from [61] with permission.
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further studies with the ultimate aim of using this 
treatment approach in patients.
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